Mycobacterium szulgai
| style="background:#Template:Taxobox colour;"|Mycobacterium | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| style="background:#Template:Taxobox colour;" | Scientific classification | ||||||||||||||
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mycobacterium szulgai is a species of Mycobacterium. It is a Scotochromogen and is currently ungrouped. It is known to cause skin infections.[1]
Treatment
Antimicrobial Regimen
- 1. in vitro susceptibility[2]
- M. szulgai is susceptible in vitro to most antituberculous drugs including Quinolones and newer Macrolides.
- 2. Pulmonary infection
- Preferred regimen: three- or four-drug regimen that includes 12 months of negative sputum cultures while on therapy
- 3. Extrapulmonary infection
- Preferred regimen: combination antituberculous medications based on in vitro susceptibilities for 4 to 6 months
References
- ↑ Hizawa K, Nagata Y, Kudo T, Taniguchi M, Matsumoto T, Iida M (September 2009). "[A case of steroid-dependent ulcerative colitis complicated by skin infection of Mycobacterium szulgai]". Nippon Shokakibyo Gakkai Zasshi (in Japanese). 106 (9): 1359–63. PMID 19734708.
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.